Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954

被引:61
|
作者
Race, Paul R.
Lovering, Andrew L.
White, Scott A.
Grove, Jane I.
Searle, Peter F.
Wrighton, Christopher W.
Hyde, Eva I. [1 ]
机构
[1] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
[3] ML Labs, Keele ST5 5SP, Staffs, England
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会;
关键词
nitroreductase; CB1954; protein engineering; X-ray structure; gene therapy;
D O I
10.1016/j.jmb.2007.02.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme-prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this systeni. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and FIN affect the interactions with nicotinic acid. The structure of double mutant N71S/FI24K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:481 / 492
页数:12
相关论文
共 28 条
  • [21] E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy:: role of arylamine N-acetlytransferase 2
    Mitchell, D. J.
    Minchin, R. F.
    CANCER GENE THERAPY, 2008, 15 (11) : 758 - 764
  • [22] Gene therapy for pancreatic cancer: In vivo killing of tumour cells expressing E-coli nitroreductase following administration of the prodrug CB1954
    Green, NK
    Youngs, DJ
    Young, LS
    Kerr, DJ
    Neoptolemos, JP
    Searle, PF
    GUT, 1997, 41 : A188 - A188
  • [23] Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E-coli nitroreductase gene
    Searle, PF
    Weedon, SJ
    McNeish, I
    Gilligan, MG
    Ford, MJ
    Friedlos, F
    Springer, CJ
    Young, LS
    Kerr, DJ
    CANCER GENE THERAPY, 1997, 4 (05) : 304 - 304
  • [24] E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2
    D J Mitchell
    R F Minchin
    Cancer Gene Therapy, 2008, 15 : 758 - 764
  • [25] THE TOXICITY AND MUTAGENICITY OF THE ANTITUMOR DRUG 5-AZIRIDINO-2,4-DINITROBENZAMIDE (CB1954) IS GREATLY REDUCED IN A NITROREDUCTASE-DEFICIENT STRAIN OF ESCHERICHIA-COLI
    VENITT, S
    CROFTONSLEIGH, C
    MUTAGENESIS, 1987, 2 (05) : 375 - 381
  • [26] THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .2. A COMPARISON OF AN ESCHERICHIA-COLI NITROREDUCTASE AND WALKER DT DIAPHORASE
    KNOX, RJ
    FRIEDLOS, F
    SHERWOOD, RF
    MELTON, RG
    ANLEZARK, GM
    BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) : 2297 - 2301
  • [27] THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .1. PURIFICATION AND PROPERTIES OF A NITROREDUCTASE ENZYME FROM ESCHERICHIA-COLI - A POTENTIAL ENZYME FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)
    ANLEZARK, GM
    MELTON, RG
    SHERWOOD, RF
    COLES, B
    FRIEDLOS, F
    KNOX, RJ
    BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) : 2289 - 2295
  • [28] Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E-coli nitroreductase gene
    Green, NK
    Youngs, DJ
    Neoptolemos, JP
    Friedlos, F
    Knox, RJ
    Springer, CJ
    Anlezark, GM
    Michael, NP
    Melton, RG
    Ford, MJ
    Young, LS
    Kerr, DJ
    Searle, PF
    CANCER GENE THERAPY, 1997, 4 (04) : 229 - 238